Jupiter Neurosciences Inc
jupiterneurosciences.comWhat Do They Do?
Develops JOTROL-based drug candidates for central nervous system disorders and rare diseases, and sells Nugevia wellness supplements to consumers.
10-K for FY2025, filed Apr 1, 2026Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is…View ↗
The first products under the Nugevia brand, focusing on supporting longevity and health span are available for sale and shipments began in…View ↗
The Company’s pharmaceutical product pipeline is built around its proprietary platform product, JOTROL™ an enhanced oral formulation of…View ↗
How Do They Make Money?
The company sells Nugevia supplements, with sales counted when products ship or are delivered, depending on the arrangement.
10-K for FY2025, filed Apr 1, 2026
$21.8K
-
10-K for FY2025, filed Apr 1, 2026
$21.8K ↗
Who Are Their Customers?
Consumers buy Nugevia supplements directly through the company’s e-commerce website; the initial U.S. launch used a direct-to-consumer model.
10-K for FY2025, filed Apr 1, 2026
Do Revenues Turn Into Profits?
No. It lost $8.6M in FY2025.
How Are They Changing?
-
Aug 28, 2026
Nasdaq determined to delist the company's common stock
Jupiter intends to appeal, and says its hearing request is expected to stay further action pending a decision.
Sources
8-K, filed Aug 28, 2026
On August 27, 2026, Jupiter Neurosciences, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications…View ↗
-
Jul 21, 2026
Jupiter entered an exclusive U.S. license for ALA-002
The license covers development, manufacture and commercialization of ALA-002 products in the United States.
Sources
8-K, filed Jul 21, 2026
Reference is made to the Current Report on Form 8-K filed by Jupiter Neurosciences, Inc. (the “Company”) with the Securities and Exchange…View ↗
Who Do They Compete With?
Competes with Biogen, Eli Lilly, Cognition Therapeutics, Anavex Life Sciences, Eisai, Sanofi Genzyme, RegenexBio, Sigilon Therapeutics, Sangamo Therapeutics, Cyclerion Therapeutics, and Abliva
10-K for FY2025, filed Apr 1, 2026Several companies are actively developing treatments for Alzheimer’s disease, each with unique approaches and challenges. Biogen’s Aduhelm…View ↗
Loading...
